ANUH PHARMA
|
ANUH PHARMA Last 5 Year Financial Ratios History
[Standalone]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 4.10 | 9.45 | 11.98 | 7.22 | 6.10 |
| CEPS(Rs) | 5.23 | 5.60 | 6.85 | 4.58 | 4.24 |
| DPS(Rs) | 1.50 | 1.50 | 2.50 | 2.00 | 1.75 |
| Book NAV/Share(Rs) | 35.14 | 65.06 | 58.11 | 48.14 | 42.66 |
| Tax Rate(%) | 24.30 | 22.38 | 23.31 | 23.78 | 21.88 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 7.37 | 9.23 | 11.65 | 9.78 | 9.67 |
| EBIT Margin(%) | 7.08 | 9.34 | 12.19 | 9.10 | 8.29 |
| Pre Tax Margin(%) | 6.96 | 9.15 | 12.04 | 8.96 | 7.97 |
| PAT Margin (%) | 5.27 | 7.10 | 9.24 | 6.83 | 6.22 |
| Cash Profit Margin (%) | 6.73 | 8.42 | 10.56 | 8.66 | 8.66 |
| Performance Ratios | |||||
| ROA(%) | 7.76 | 9.97 | 14.14 | 9.63 | 8.99 |
| ROE(%) | 12.10 | 15.34 | 22.56 | 15.90 | 15.11 |
| ROCE(%) | 16.02 | 19.77 | 29.66 | 21.05 | 19.33 |
| Asset Turnover(x) | 1.47 | 1.40 | 1.53 | 1.41 | 1.44 |
| Sales/Fixed Asset(x) | 6.26 | 5.96 | 6.37 | 5.31 | 4.97 |
| Working Capital/Sales(x) | 3.14 | 3.37 | 3.50 | 3.62 | 3.84 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.16 | 0.17 | 0.16 | 0.19 | 0.20 |
| Receivable days | 106.48 | 111.12 | 101.36 | 105.71 | 90.17 |
| Inventory Days | 52.06 | 41.04 | 41.55 | 52.54 | 59.98 |
| Payable days | 105.46 | 109.35 | 110.65 | 125.45 | 117.42 |
| Valuation Parameters | |||||
| PER(x) | 16.39 | 7.88 | 10.25 | 11.03 | 14.09 |
| PCE(x) | 12.83 | 13.30 | 17.93 | 8.70 | 10.13 |
| Price/Book(x) | 1.91 | 2.29 | 4.23 | 1.65 | 2.01 |
| Yield(%) | 2.23 | 1.01 | 1.02 | 2.51 | 2.04 |
| EV/Net Sales(x) | 0.86 | 1.11 | 1.89 | 0.74 | 0.86 |
| EV/Core EBITDA(x) | 9.98 | 10.38 | 13.94 | 6.77 | 7.94 |
| EV/EBIT(x) | 12.04 | 11.83 | 15.45 | 8.14 | 10.27 |
| EV/CE(x) | 1.89 | 2.19 | 4.18 | 1.63 | 1.93 |
| M Cap / Sales | 0.87 | 1.13 | 1.90 | 0.76 | 0.89 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 16.65 | 2.24 | 22.66 | 8.39 | 12.66 |
| Core EBITDA Growth(%) | -6.24 | -19.20 | 51.68 | 9.98 | -5.38 |
| EBIT Growth(%) | -11.36 | -21.47 | 64.40 | 18.46 | 0.30 |
| PAT Growth(%) | -13.32 | -21.16 | 66.00 | 18.38 | 7.47 |
| EPS Growth(%) | -56.66 | -21.16 | 66.00 | 18.38 | 7.47 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | 0.03 | 0.01 | - | 0.01 |
| Current Ratio(x) | 2.22 | 2.11 | 2.22 | 1.91 | 1.98 |
| Quick Ratio(x) | 1.50 | 1.69 | 1.72 | 1.46 | 1.37 |
| Interest Cover(x) | 57.78 | 50.10 | 82.82 | 64.61 | 25.76 |
| Total Debt/Mcap(x) | - | 0.01 | - | - | 0.01 |
Compare Financial Ratios of peers of ANUH PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| ANUH PHARMA | ₹793.4 Cr | 0.2% | 0.3% | -18.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹467,630.0 Cr | -2.6% | 2.4% | 14.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹221,666.0 Cr | 6.5% | 23.3% | 25.3% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹190,108.0 Cr | 2.6% | 3% | 33.5% | Stock Analytics | |
| CIPLA | ₹117,139.0 Cr | -1.1% | -0.2% | -7.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹97,990.9 Cr | 2.6% | -13.3% | -10.7% | Stock Analytics | |
ANUH PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ANUH PHARMA | 0.2% |
0.3% |
-18.8% |
| SENSEX | 1.2% |
0.4% |
-2.9% |
You may also like the below Video Courses
